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Abstract
Background: South Africa is likely to be the first country in the world to host an adolescent HIV
vaccine trial. Adolescents may be enrolled in late 2007. In the development and review of
adolescent HIV vaccine trial protocols there are many complexities to consider, and much work
to be done if these important trials are to become a reality.
Discussion: This article sets out essential requirements for the lawful conduct of adolescent
research in South Africa including compliance with consent requirements, child protection laws,
and processes for the ethical and regulatory approval of research.
Summary:  This article outlines likely complexities for researchers and research ethics
committees, including determining that trial interventions meet current risk standards for child
research. Explicit recommendations are made for role-players in other jurisdictions who may also
be planning such trials. This article concludes with concrete steps for implementing these important
trials in South Africa and other jurisdictions, including planning for consent processes; delineating
privacy rights; compiling information necessary for ethics committees to assess risks to child
participants; training trial site staff to recognize when disclosures trig mandatory reporting
response; networking among relevant ethics commitees; and lobbying the National Regulatory
Authority for guidance.
Background
Adolescents have been involved in trials for vaccines to
prevent sexually transmitted infections/diseases like
Human Papilloma Virus (HPV) and Herpes Simplex Virus
type-2, (HSV-2), both in the developed and the develop-
ing world [1,2]. In Merck's ongoing quadrivalent HPV vac-
cine program, at least 12 000 young people between the
ages of 9–24 have received the HPV vaccine, with approx-
imately 20% of these being boys and girl between the ages
of 9–15 (Merck, personal communication). Infants have
also participated in phase I HIV vaccine trials and cur-
rently Uganda is enrolling HIV exposed infants in a phase
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I vaccine trial [3,4]. However, no HIV uninfected adoles-
cents have participated in HIV vaccine trials anywhere in
the world.
Because adolescents are severely affected by the HIV epi-
demic [5-7], they should be the main recipients/benefici-
aries of a successful HIV vaccine. To achieve this, there will
be a need to license the vaccine for use in this age group.
Adolescent participation in HIV vaccine trials is therefore
paramount in order to determine the safety profile, appro-
priate dosing schedules and the degree of immunogenic-
ity in this age group. Adolescent trials are also necessary as
vaccine responses may differ because of physiological or
hormonal differences between adults and younger adoles-
cents [8,9]. Delays in licensure for use in adolescents
could retard the control of the HIV epidemic, as was seen
in the control of the Hepatitis B epidemic in the United
States where there was no clear strategy to include infants,
children and adolescents in the vaccination program [10].
South African researchers anticipate enrolling 16–18 year
olds in a phase IIb proof of concept vaccine trial towards
the end of 2007. These adolescents will be at high risk of
HIV infection. Further, it is envisaged that 12–15 year old
adolescents will be involved in phase I/II trials as early as
2008. The phase I/II studies will determine the safety, tol-
erability and preliminary immunogenicity in pre-teens
and young adolescents of candidate vaccines that are cur-
rently being tested for preliminary efficacy in adults and
older adolescents. The phase I/II studies will involve a
small number of healthy adolescents, at low risk of acquir-
ing HIV infection.
In the development and review of adolescent HIV vaccine
protocols, there are many legal complexities that need to
be addressed. This article sets out complexities linked to
consent requirements; special legal protections for chil-
dren in need of care and protection; and procedural
requirements for the approval of such research. These
complexities are not unique to South Africa because in
many jurisdictions where such trials may occur adolescent
participants will have limited legal capacity, and the
enrolment of adolescents must take account of local laws
dealing with, for e.g., the age of lawful consent to sex and
obligations on certain adults to report abuse. Further-
more, like South Africa, very few developing countries will
have dedicated research laws. Therefore this article also
discusses implications of these legal complexities for role-
players in other jurisdictions. We make a series of recom-
mendations for additional work that needs to be done in
order to realize the optimal involvement of adolescent
participants. We refer to "child" as a person under the age
of 18 [11,12] and a "minor" as a person under the age of
21 [13] soon to change to 18 [14]. We use the term "ado-
lescent" to refer to persons between the ages 12 and 18
[15].
HIV vaccine trials
Phase I/II HIV vaccine trials with adolescents would aim
to recruit a small number of healthy adolescents who are
at low risk of acquiring HIV infection. Phase IIb trials will
recruit adolescents at higher risk of HIV infection. The tri-
als themselves will comprise of a number of interventions,
including a general physical examination and medical his-
tory-taking; assessment of HIV risk factors including per-
sonal questions about sex and substance use; personalized
risk reduction counseling; administration of an experi-
mental HIV vaccine or placebo via injection; blood draws
for laboratory safety and immunogenicity testing; and reg-
ular testing for HIV infection. Adolescents will be classi-
fied as "low risk" if they are not sexually active as defined
as primary abstinence (no sexual activity ever initiated) or
secondary abstinence (no sexual activity for six months).
Although many interventions in a phase I trial may not
hold out the prospect of direct benefit for adolescent par-
ticipants, there are interventions that may benefit partici-
pants, such as personalised risk reduction counselling.
Additionally, there may be associated benefits such as
identification of medical conditions like hypertension
and early referral to care, access to care for intercurrent ill-
ness or reproductive health, and referral for abuse. Despite
conceptual difficulties in classifying whole protocols as
either "therapeutic" or "non-therapeutic research" [16] it
is possible that phase I safety trials in South Africa would
be classified as "non-therapeutic" because of the prepon-
derance of interventions that will not confer direct bene-
fit.
Discussion
The ethical-legal framework for child research in South 
Africa
Currently South Africa does not have a comprehensive
ethical-legal framework regulating research with children.
The Constitution (s12(2) (c)) prohibits research without
informed consent [12]. However, there is currently no
health or child care legislation dealing directly with child
or adolescent research. Health rights are found scattered
through the Constitution, common law and various stat-
utes and they do not set out when and how children may
participate in research. The primary piece of legislation
dealing with the protection of children is the Child Care
Act [11] which provides for some of a child's health rights
but does not deal with research. In May 2005 the National
Health Act [17] became effective. It creates a national
framework for health care delivery. Section 71 of the Act
covers health research with human subjects including
minors. This section has not been implemented as yet and
it is unlikely that it will come into effect before the middle
of 2007. In June 2006 a new Children's Act [14] wasBMC Medical Ethics 2007, 8:5 http://www.biomedcentral.com/1472-6939/8/5
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promulgated that will repeal the existing Child Care Act,
however, it is not yet in operation. In addition, there are 4
major sets of ethical guidelines in South Africa bearing on
child research [18-21]. Recently, draft regulations for
research with human subjects were published for public
comment [22]. It is envisaged that once the regulations
are finalized, s71 will be implemented. Given this state of
flux, this article refers to both current and future ethical-
legal obligations.
Key considerations for lawful adolescent HIV vaccine trials
For research to be lawful within any legal system it must
comply with substantive and procedural requirements
established in law and ethical guidelines. The nature of
these obligations varies from system to system, however
most establish requirements relating to consent, ethical
review and scientific validity. In South Africa, there are
three key issues that must be taken into account when
ensuring that adolescent research is lawful. These are elab-
orated on below:
(i) Consent requirements must be met
(ii) Legal obligations in child protection laws must be
complied with; and
(iii) There must be compliance with requirements for eth-
ical and regulatory review.
(i) Informed consent
Who must consent?
In South Africa, for adolescent trials to be lawful, consent
must given by a participant with legal capacity to consent,
or if not competent, by a person with the authority to con-
sent on the participant's behalf.
Independent consent by adolescents
In terms of current South African law, there is no provi-
sion setting out when children may provide their own
independent consent to research. However children may
consent independently to medical treatment from the age
of 14 [11,23]. Accordingly some legal scholars have
argued that children of 14 and older can consent inde-
pendently to "therapeutic" research [24] while others
have argued that such an equation cannot be easily
made.25 With regard to "non-therapeutic" research some
have argued for independent child consent if there is no
risk at all [25] while others have asserted that proxy con-
sent is always required, and can indeed only be given in
restricted circumstances [24]. In terms of current South
African law, there is also no guidance on who may provide
consent for child participation in research if children lack
this capacity themselves. It appears that most South Afri-
can research ethics committees (RECs) have relied on the
recommendations made in ethical guidelines which
broadly require parental or guardianship consent for
research plus the assent of the child [20,21].
Consent by a parent or legal guardian and the child if capable of 
understanding
However under future law, in terms of s 71 of the National
Health Act (NHA) [17] consent will have to be obtained
from a parent or legal guardian until the age of majority is
reached. Other care-givers or custodians will not have the
authority to provide consent for child research [23]. Pres-
ently, minority ends at 21 [13] however it will soon drop
to 18 [14]. While future law will require consent from a
sole parent or guardian, some ethical guidelines require
consent from both parents (if reasonably available)
depending on research risks in relation to direct benefit
for the child participant [18,20].
The NHA also specifies that consent must also be
obtained from minors if they are "capable of understand-
ing" [17]. There is an implied legal obligation to obtain
assent, as assent is the means to get the child's perspective
to establish their "best interests" required by s 28(2) of the
Constitution for every matter concerning the child [12].
The NHA means that the standard for persons under the
age of majority is not necessarily assent but rather that
when children have sufficient comprehension it is their
consent that shall be required [28]. That is, the Act
requires persons who are legal minors to consent rather
than assent if they have sufficient comprehension. How-
ever, assessment of understanding is potentially compli-
cated [29,30]. While trial sites tend to favour forced-
choice checklists to assess understanding because they are
objective and easy to administer [31,32], there is some
evidence that they may yield higher scores of understand-
ing than open-ended measures like narratives [33] and
may be vulnerable to rote memorisation [30,34].
Another complexity is that given that adolescents will not
be able to consent to research independently complex pri-
vacy issues arise. Although the NHA does not specifically
refer to a child/minor's right to privacy in research, a child
does have a constitutional and common law right to pri-
vacy. In terms of this right a person with an expectation of
privacy is entitled to keep aspects of their life private pro-
vided this expectation is regarded as reasonable by society
[35]. This is also referred to as the "legitimate expectation"
of privacy test [36]. In circumstances where a child does
not have a right to privacy, researchers may disclose infor-
mation to the parent or legal guardian as a legitimate
party in the research relationship who has provided con-
sent for participation. Applying this test to adolescent
research is complex because it is uncertain when society
would regard an adolescent's expectation of privacy to be
reasonable.  One example: if an adolescent tests HIV
infected during a trial, the adolescent may expect theBMC Medical Ethics 2007, 8:5 http://www.biomedcentral.com/1472-6939/8/5
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researchers to keep such information confidential, and
society may regard this as reasonable given that adoles-
cent's have the right to HIV testing and confidentiality
from the age of 14 outside of a trial context [11]. However,
given that parents have provided consent to participation
in a trial involving regular HIV testing and given that HIV
infected adolescents would require care and support, it
may be reasonable to ask adolescent trial participants to
waive their privacy rights by agreeing to disclose their HIV
status to a trusted adult within a certain time frame.
A second example: adolescents may have expectations of
privacy regarding their sexual risk information. In this
instance society may not regard this as reasonable as par-
ents are legally responsible for their children and are
required to protect them from harm. Withholding infor-
mation from parents regarding risks facing their children
such as experimentation with drugs or alcohol may mean
that a parent is unable to meet their legal obligations to
protect the child. Therefore a parent may be entitled to
risk information. However parents could be asked to
waive their right to access such information, if other safe-
guards are in place like referral to counselling, and if the
information does not involve significant risks and crimi-
nal activity like sexual abuse.
A further complexity is that there is evidence that adoles-
cents when compared to adults are less likely to spontane-
ously consider risks and benefits, [37] are less likely to
evaluate long-term consequences of decisions, [38-40] are
more likely to place weight on benefit than risk, [41] are
more likely to be short-term focused, [42] and are less
likely to recognize the vested interests of others [43]. More
risky decisions may be made in groups than individually
[44]. Obviously parental consent provides some degree of
protection against immature decision-making, however,
researchers should try to enhance adolescent understand-
ing to the fullest extent possible.
Recommendations
For South African trials, we recommend that HIV vaccine
trial researchers anticipate a future change in the age of
majority. Researchers could currently consider obtaining
parental consent for all under-21's, and be prepared to
submit protocol amendments to obtain expedited
approval to obtain parental consent for under-18's when
the change in the law becomes effective. For trials requir-
ing large numbers of adolescents to be enrolled, research-
ers must consider how they will assist primary care-givers
looking after orphans with the complex legal process of
transferring guardianship to enable them to provide law-
ful consent to adolescent participation. For other jurisdic-
tions, we recommend that clarity be obtained on whether
adolescents can consent independently to research or if they
cannot, which adults have the capacity to provide proxy con-
sent byexamining research specific legislation, legislation
that establishes the age of majority or that provides ado-
lescents with capacity to consent to specific acts such as
medical treatment. Child Care legislation may also
describe the persons with legal authority to act on behalf
of children. Ethical guidelines should also be consulted
for advice.
We recommend that South African researchers consider
how they will establish when an adolescent has the neces-
sary depth of understanding for the higher standard of
competence required for consent [45] or whether adoles-
cents meet the less strenuous requirements of assent,
including basic comprehension of purpose and proce-
dures, and right to withdraw [46] and the ability to indi-
cate a preference [47]. No-one has yet developed an
"assent assessment tool" or described what such a tool
would assess [48]. As true-false checklists may be inappro-
priately constituted for the necessary probing required to
establish depth of understanding of complex trial con-
cepts [49], sites must consider open-ended measures that
probe understanding. Stakeholders outside of South
Africa are also likely to be concerned with appropriate
"tests" of understanding.
Privacy rights for sexual risk information and HIV status
will have to be delineated and both parents and adoles-
cents will have to understand what information parents
will/will not have access to. In South Africa this detailed
work will hinge on the "legitimate expectation" of privacy
test. In other jurisdictions, however, this analysis should
also be done using relevant legal principles.
In all settings considering trials, consent processes should
be designed that are sensitive to characteristics of adoles-
cent decision-making. While group formats, like Vaccine
Discussion Groups, may be effective for disseminating
information about trials, cognizance should be taken of
how peer influence may affect the evaluation of risk. It is
likely that extended interpersonal contact with a knowl-
edgeable trial site counsellor may effectively improve
understanding [34] and counsellors should be trained to
enhance understanding of potential long-term harms.
Adolescent-friendly materials should also be developed
with advice from adolescent consultants [50].
What can be consented to?
In order for adolescent participation in HIV vaccine trials
to be lawful in South Africa, current common law require-
ments must be met, that is consent to such research must
be in accordance with public policy [23]. In other words
consent to the harm or risk of harm must be legally per-
mitted [51]. To determine this, it has been proposed that,
amongst other factors, the research must present accepta-
ble standards of risk [23]. Neither current South AfricanBMC Medical Ethics 2007, 8:5 http://www.biomedcentral.com/1472-6939/8/5
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law nor future law (s71 of the NHA) [17] provides a clear
standard for acceptable research risk [23]. Draft regula-
tions [22] assert that research with children is only per-
missible if it poses minimal risk, or greater than minimal
risk but holds out benefit for the child. An important third
category is not included in the draft regulations – namely,
research that poses more than minimal risk but holds out
no prospect of direct benefit. South African ethical guide-
lines are not unanimous on risk standards however they
are approaching harmonisation [52]. Three out of four
South African ethical guidelines [18-20] assert that when
the intervention or research does not hold out the prospect
of direct benefit, the allowable risk level is a minor
increase over the risks of daily life or routine medical and
psychological tests ("everyday risk"); if justified by the
risk-knowledge ratio. The one guideline in exception [21]
permits no increase at all [53]. Most South African ethical
guidelines assert that when the intervention or the
research does hold out the prospect of benefit there is no
explicit upper limit of risk however the risks must be jus-
tified by the benefit. It is likely that if HIV vaccine trials are
reviewed by a number of RECs, they will disagree on how
to apply the risk standards for non-beneficial research
[54]. It is possible that different RECs may categorise the
same non-beneficial intervention like blood draws for lab
testing as minimal risk (permitted), a minor increase over
minimal risk (permitted) or more than that (not permit-
ted).
Recommendations
Because the majority of recent guidelines now require it,
we recommend that RECs become familiar with "compo-
nent analysis" to demarcate interventions as beneficial or
non-beneficial [55] and to assess if non-beneficial inter-
ventions meet national risk standards. Investigators
should begin now to prepare documentation on risks so
that RECs can make these complex assessments for both
product related risks and social harms. Data should be
available, at least in part, from prior trials with less vulner-
able participants such as adults. Inputs should be made to
the draft regulations to bring them in line with national
ethical guidelines that set acceptable standards of risk for
non-beneficial research.
(ii) Complying with legal obligations in child protection 
laws
It is a principle of international law that special legal pro-
tections ought to exist to protect persons during child-
hood [56]. South Africa, like most other states therefore
have developed a range of special laws that protect chil-
dren against maltreatment and abuse. For example, in
South Africa, the Sexual Offences Act [57] contains spe-
cific offences relating to children, such as the criminaliza-
tion of sex under the age of 16 and child prostitution in s
14(1)(a), 14(3) and 9. Consent is not a defense to these
crimes [58]. Furthermore while there is generally no legal
obligation to report a crime, South African law includes
special protection for children who may be facing abuse,
ill-treatment or neglect. The Child Care Act11 in section 42
requires  medical practitioners, amongst others, to report
suspected ill-treatment, abuse or neglect of children to the
Department of Social Development. Failure to report is a
criminal offence. Additionally, the Family Violence Act
[59] states that any person who examines, treats, attends to,
advises, instructs or cares for any child, who suspects that
the child has been ill-treated, must report this to a Com-
missioner of Child Welfare, a social worker or the police.
The future Children's Act [14] in section 150 will oblige
any person to identify children in need of care and protec-
tion (e.g. living in a child headed household, required to
perform child labour, being maltreated, abused, or
exploited) and to refer these to a social worker. In terms of
these laws, it is argued that HIV vaccine trial staff would
have a legal duty to report abuse or ill-treatment disclosed
by adolescent in a trial. Due to the broad meaning of
terms such as "ill-treatment" disclosures of rape and or
some cases of under-age sex would need to be reported to
the appropriate authorities.
Recommendations
We recommend that study staff be trained to recognise
those disclosures that trigger a mandatory reporting
response. Consent procedures should inform parents and
adolescents about this limit to confidentiality. The proto-
col should not only spell out how formalistic legal
requirements will be met but broader ethical require-
ments to promote children's' welfare, such as whether
such information will be disclosed to parents. Further-
more, stakeholders in other jurisdictions will need to
establish whether any special protections exist for chil-
dren, such as the mandatory disclosure of HIV status, and
if any special obligations are placed on researchers regard-
ing children in need of care or protection. Such laws may
either be found in criminal codes or in child specific laws.
(III) There is compliance with procedural requirements for 
ethical and scientific review of the research
To be lawful, research must be approved by the relevant
authorities.
Ethical approval by an REC
The NHA (s73) [17] sets out the current legal obligations
of RECs. It provides that RECs must approve research
where it meets the "ethical standards of the committee". It
is likely that the MRC (2003) [19] guidelines drafted for
HIV vaccine trials will need to be consulted which allow
child participation provided risk standards, consent and
scientific necessity requirements are met.BMC Medical Ethics 2007, 8:5 http://www.biomedcentral.com/1472-6939/8/5
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Authorisation for the use of a genetically modified organism
In terms of current law, for all HIV vaccine trials, a permit
must be obtained from the Executive Council of Geneti-
cally Modified Organisms for any research into a geneti-
cally modified organism such as an HIV vaccine. This is a
body established within the Department of Agriculture
[60].
Approval by the Medicines Control Council (MCC)
In terms of current law [61], the Minister of Health in con-
sultation with the MCC has the power to issue regulations
on the control and conduct of clinical trials. These have
been issued and provide (amongst other things) that clin-
ical trials must be conducted in accordance with Good
Clinical Practice guidelines issued by the MCC or the
Department of Health from time to time [62]. While the
MCC [63] has also prepared a set of guidelines for phase I
trial applications they do not appear to have issued any
guidance on adolescents.
Ministerial consent for "non-therapeutic" research
Phase I adolescent HIV vaccine trials may be classed as
"non-therapeutic". When Section 71(3)(b)(iv) of the
NHA [17] becomes effective, "non-therapeutic" research
on children may not be done without first obtaining con-
sent from the Minister of Health. S/he may not consent to
such research if amongst others it poses a "significant risk"
to the health of a child, or "some" risk that is not out-
weighed by benefit. No definition is provided of "signifi-
cant risk", and this is not provided for in the draft
regulations [22]. This condition adds an additional layer
of administrative scrutiny [23,27]. However, much
remains to be clarified, including which research falls into
its scope, its place in the sequence of approvals investiga-
tors must obtain, and the entity that will carry out this
function. This detail is also not provided in the draft reg-
ulations [22].
Recommendations
We recommend that RECs begin to network with each
other to build consensus about adolescent trials, includ-
ing the acceptability of trial interventions in terms of
national risk standards. Like regulatory authorities in all
the jurisdictions planning adolescent HIV vaccine trials,
the Medicines Control Council should be requested to
articulate the data it will require to firstly, allow adoles-
cents into trials and secondly, to license an adolescent vac-
cine. Very specifically, in the South African setting, we
recommend that researchers anticipate the public policy
assessment that the Minister will have to undertake by
framing their protocols in a way that assists the Minister,
or delegated authority, to make a speedy determination.
RECs in all jurisdictions planning such trials should be
aware that public policy considerations are becoming
increasingly important in the regulation of research and
are being reflected in law. Therefore research-specific and
health specific laws should be consulted to establish
whether there are specific limits on certain forms of
research. Researchers who craft their protocols with
thoughtful attention to ethical guidelines may meet most,
if not all, of the legal requirements. Where the law is
unclear, researchers should consult with their REC or get
legal advice from a lawyer trained in research ethics and
law.
Conclusion
HIV vaccine trials with adolescents will pose legal com-
plexities for all jurisdictions in which they will take place.
Complexities may stem from a lack of legal guidance, or a
lack of tools for using legal concepts, and some dishar-
mony between ethical guidelines [22]. The legal complex-
ities are not, however, insurmountable. Stakeholders
preparing for these trials in South Africa and other coun-
tries should take on the following as a matter of urgency:
1. Investigators must plan for the complex consent proc-
esses that will be required including assessment of under-
standing
2. Investigators must compile the information necessary
for RECs to assess potential risks to child participants
(both social and physical) to establish if these meet
national risk standards for child research
3. It must be determined whether adolescents have pri-
vacy rights to their sexual risk information and HIV status
and if so, whether these will be waived or not
4. Trial site staff must be trained to recognize when ado-
lescent disclosures (e.g. of abuse or neglect) will trigger a
mandatory reporting response
5. RECs that will review adolescent protocols should
begin to network with one another to prepare for a coor-
dinated response to similar research protocols, and
6. The national regulatory authority should outline the
data they will need to allow adolescent trials and allow
licensure of an adolescent vaccine.
A journey of a 1000 miles starts with a single step.
Summary
Enrolling adolescents in HIV vaccine trials will pose legal
complexities in all jurisdictions where these will occur,
likely beginning with South Africa. Investigators and REC
will have to deal with i) consent requirements (e.g. who
must consent? what can be consented to?); ii) obligations
to protect children from abuse and maltreatment (e.g.
responding to disclosures by adolescents that they haveBMC Medical Ethics 2007, 8:5 http://www.biomedcentral.com/1472-6939/8/5
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been raped, or are having unlawful sex) and iii) proce-
dural requirements for approval of the research (e.g. need
for guidance from the National Regulatory Authority).
Jurisdictions planning adolescent HIV vaccine trials, like
South Africa, will have to consider a range of networking,
tool development and training processes to ensure that
sound adolescent trials are a reality.
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